ProtonDx's core technology builds on several years of innovative research in diagnostics and sample extractions, fuelled by unique collaborations between engineering, medicine and molecular biology. The spin-out company was founded in 2020 at Imperial College London and is based on Lab-on-Chip diagnostic technology.
The team developed Lacewing, a point-of-care device that detects parasite DNA from a few microliters of finger-prick blood in 15-30 minutes. The team also developed ramps up for Dragonfly, a point-of-care, in vitro diagnostic device that was used at the 2022 Winter Olympics and Commonwealth Games. Today, they are continuing to innovate and develop diagnostics.
Imperial researchers working on ProtonDX:
- Dr Jesus Rodriguez Manzano (Co-Founder and Chief Scientific Officer)
- Professor Pantelis Georgiou (Co-Founder and Director)
- Dr Nick Moser (Co-Founder and Chief Technology Officer)
- Dr Ivana Pennisi
